{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:33Z","timestamp":1788416013699,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Chromophobe renal cell carcinoma (chRCC) is a rare subtype of kidney cancer with biological and clinical features that differ significantly from clear cell renal cell carcinoma (ccRCC). While adjuvant treatments have evolved for ccRCC, chRCC has been excluded or understudied in clinical trials, which has led to insufficient histology-specific data to guide postoperative treatment. This research aimed to summarize and critically appraise the current evidence regarding adjuvant therapies for chRCC, highlight existing limitations in the literature, and identify priorities for future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature review was performed using PubMed and Google Scholar with search terms including \u201cCarcinoma, Renal cell, Chromophobe, RCC, adjuvant, treatment, postoperative therapy, kidney cancer\u201d. The search was limited to the last 10 years and included various study designs, ranging from phase III trials to case reports, that specifically addressed chRCC rather than grouping it broadly under non-clear cell RCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Current clinical evidence does not support the routine use of adjuvant systemic therapies in chRCC. The phase III EVEREST trial failed to demonstrate a statistically significant improvement in recurrence-free survival for the mTOR inhibitor everolimus in the chRCC subgroup. Similarly, the ECOG ACRIN E2805 trial found that adjuvant VEGFR-targeted therapies, such as sunitinib and sorafenib, resulted in excessive toxicity without providing a disease-free survival benefit over placebo. Data on immune checkpoint inhibitors like pembrolizumab and nivolumab remain limited to metastatic settings with low objective response rates, resulting in insufficient evidence and a lack of expert consensus for their adjuvant use in chRCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is a substantial lack of evidence supporting any reliable adjuvant therapy for chRCC, leaving high-risk patients without proven options after nephrectomy, and questioning the consistency of the extrapolation from metastatic clear-cell populations. However, given the rarity of chRCC and its comparatively low recurrence risk, a dedicated adjuvant randomized trial may be neither statistically nor logistically feasible; priorities should instead include first establishing an effective systemic therapy in the metastatic setting, pursuing pooled non\u2013clear cell or registry-based collaborations, and developing biomarker-driven patient selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1910114","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:49Z","timestamp":1788412969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant therapy in chromophobe renal cell carcinoma: current evidence and unmet needs"],"prefix":"10.3389","volume":"16","author":[{"given":"Niovi","family":"Bejjani","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, University Medical Center Hotel Dieu de France, Faculty of Medicine, Saint Joseph University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, University Medical Center Hotel Dieu de France, Faculty of Medicine, Saint Joseph University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"409\u2013","DOI":"10.1200\/JCO.2024.42.4_suppl.409","article-title":"Real world data on treatment of chromophobe renal cell carcinoma","volume":"42","author":"Battle","year":"2024","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.040","article-title":"Recommendations for the management of rare kidney cancers","volume":"72","author":"Giles","year":"2017","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.055","article-title":"Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience","volume":"23","author":"Patard","year":"2005","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-2247","article-title":"Adjuvant therapy in renal cell carcinoma (RCC): progress, at last","volume":"13","author":"Bueno","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B5","article-title":"Local and distant recurrence of the chromophobe renal cell carcinoma","volume":"73","author":"Armas-Alvarez","year":"2020","journal-title":"Arch Esp Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03683-9","article-title":"Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma","volume":"39","author":"Neves","year":"2021","journal-title":"World J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31821a455d","article-title":"Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution","volume":"35","author":"Przybycin","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"790.e17","DOI":"10.1016\/j.urolonc.2021.06.016","article-title":"Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma","volume":"39","author":"Pieretti","year":"2021","journal-title":"Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00666-2","article-title":"Adjuvant therapy options in renal cell carcinoma\u2014 targeting the metastatic cascade","volume":"20","author":"Fitzgerald","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.029","article-title":"Adjuvant Pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: Final overall survival analysis of the phase 3 PROTECT trial","volume":"79","author":"Motzer","year":"2021","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01800","article-title":"Adjuvant Sorafenib for renal cell carcinoma at intermediate or high risk of relapse: Results from the SORCE randomized phase III intergroup trial","volume":"38","author":"Eisen","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA418","article-title":"Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study","volume":"44","author":"Choueiri","year":"2026","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106482","article-title":"RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse","volume":"108","author":"Oza","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0607-z","article-title":"Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome","volume":"33","author":"Roldan-Romero","year":"2020","journal-title":"Mod Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub\u00e9 syndrome","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908853106","article-title":"Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2","volume":"106","author":"Hasumi","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-6-115","article-title":"Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report","volume":"6","author":"Michalaki","year":"2012","journal-title":"J Med Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00913-3","article-title":"Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"402","author":"Ryan","year":"2023","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25288","article-title":"Adjuvant everolimus in non\u2013clear cell renal cell carcinoma: A secondary analysis of a randomized clinical trial","volume":"7","author":"Gulati","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds582","article-title":"Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma","volume":"24","author":"Koh","year":"2013","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.015","article-title":"A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma","volume":"80","author":"Hutson","year":"2021","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9084","article-title":"Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non\u2013clear cell renal cell carcinoma","volume":"34","author":"Voss","year":"2016","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non\u2013clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115569","article-title":"Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study","volume":"225","author":"Gr\u00fcnwald","year":"2025","journal-title":"Eur J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00419","article-title":"Clinical review on the management of metastatic renal cell carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B37","volume-title":"US food and drug administration website","year":"2021"},{"key":"B38","unstructured":"European Medicines Agency (EMA\n          Keytruda\n          \n          2018"},{"key":"B39","unstructured":"Kidney Cancer: Nice Guideline Expert Insight"},{"key":"B40","unstructured":"FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma\n          \n          \n          FDA\n          \n          2026"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910114\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:51Z","timestamp":1788412971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910114\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1910114"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910114","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1910114"}}